Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BRANDON LENOX

Allopathic & Osteopathic Physicians Anesthesiology

NPI
1710023098
CMS profile
469116
Location
MAITLAND, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$14.90

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $14.90 1

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Merck Sharp & Dohme Corporation $14.90 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BRANDON LENOX

NPI 1710023098 · CMS profile ID 469116

Allopathic & Osteopathic Physicians / Anesthesiology

MAITLAND, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1710023098?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BRANDON LENOX, NPI 1710023098, CMS profile ID 469116. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1710023098?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). BRANDON LENOX, NPI 1710023098, CMS profile ID 469116. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1710023098?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
BRANDON LENOX, NPI 1710023098, CMS profile ID 469116, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1710023098?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $14.90 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme Corporation $14.9005/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848369435 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $11.87 1
PY2021 $14.90 1
PY2022 $289.02 3
PY2023 $141.36 2
PY2024 $2,161.67 16
PY2025 $3,301.84 7

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $13,276,611.80 216
PY2024 Principal investigator $6,638,229.38 94
PY2023 Recipient $18,535.52 1
PY2023 Principal investigator $6,796,584.13 63
PY2022 Recipient $75,198.00 3
PY2022 Principal investigator $5,184,921.00 42
PY2021 Recipient $4,330.51 1
PY2021 Principal investigator $6,000.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

45 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $32,316.00 12/26/2022 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 885267069
Principal investigator 1 Janssen Research & Development, LLC $5,753.00 12/22/2022 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 885267071
Principal investigator 1 Bavarian Nordic A/S $8,897.00 12/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907245301
Principal investigator 1 Bavarian Nordic A/S $12,216.00 12/14/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907245261
Principal investigator 1 Bavarian Nordic A/S $7,099.00 12/06/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907245203
Principal investigator 1 Bavarian Nordic A/S $25,632.00 12/01/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907245179
Principal investigator 1 Bavarian Nordic A/S $19,077.00 11/15/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907245271
Principal investigator 1 Bavarian Nordic A/S $860.00 11/08/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907245225
Principal investigator 1 Janssen Research & Development, LLC $5,753.00 11/03/2022 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 885267067
Principal investigator 1 Bavarian Nordic A/S $11,579.00 11/02/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907245191
Principal investigator 1 Bavarian Nordic A/S $52,987.00 10/26/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907245329
Principal investigator 1 Bavarian Nordic A/S $51,111.00 10/18/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907245289
Principal investigator 1 Eli Lilly and Company $93,795.00 10/18/2022 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 917826167
Principal investigator 1 Bavarian Nordic A/S $14,349.00 10/12/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907245255
Recipient Eli Lilly and Company $67.00 10/10/2022 Covered Recipient Physician ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 917806315
Principal investigator 1 Bavarian Nordic A/S $10,722.00 10/07/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907245209
Principal investigator 1 Janssen Research & Development, LLC $26,482.00 10/03/2022 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 885267065
Principal investigator 1 Bavarian Nordic A/S $34,327.00 09/28/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907245341
Principal investigator 1 Bavarian Nordic A/S $30,516.00 09/20/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907245295
Principal investigator 1 Janssen Research & Development, LLC $12,300.00 09/16/2022 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 885267063
Principal investigator 1 Bavarian Nordic A/S $5,574.00 09/14/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907245265
Principal investigator 1 Bavarian Nordic A/S $43,337.00 09/07/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907245215
Principal investigator 1 Bavarian Nordic A/S $9,135.00 08/23/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907245323
Principal investigator 1 Bavarian Nordic A/S $18,007.00 08/22/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907245313
Principal investigator 1 Bavarian Nordic A/S $8,635.00 08/17/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907245283
Principal investigator 1 Bavarian Nordic A/S $4,745.00 08/11/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907245243
Principal investigator 1 Bavarian Nordic A/S $25,540.00 08/09/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907245231
Principal investigator 1 Eli Lilly and Company $8,114.00 08/04/2022 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 917830483
Principal investigator 1 Bavarian Nordic A/S $39,002.00 08/02/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907245185
Principal investigator 1 Bavarian Nordic A/S $1,986.00 07/27/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907245335
Principal investigator 1 Bavarian Nordic A/S $11,888.00 07/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907245307
Principal investigator 1 Bavarian Nordic A/S $4,731.00 07/12/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907245249
Principal investigator 1 Bavarian Nordic A/S $40,944.00 07/08/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907245219
Principal investigator 1 Bavarian Nordic A/S $49,283.00 06/30/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907245347
Principal investigator 1 Bavarian Nordic A/S $813.00 06/22/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907245317
Principal investigator 1 Bavarian Nordic A/S $35,048.00 06/16/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907245277
Principal investigator 1 Bavarian Nordic A/S $5,898.00 06/09/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907245237
Principal investigator 1 Bavarian Nordic A/S $7,864.00 06/03/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907245197
Principal investigator 1 Eli Lilly and Company $332.00 05/27/2022 Non-covered Recipient Entity
LIFE LINE SCREENING
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 917830577
Principal investigator 1 Eli Lilly and Company $901,794.00 05/09/2022 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3372689 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 917826753
Principal investigator 1 Eli Lilly and Company $3,489,071.00 02/23/2022 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 917830477
Recipient Eli Lilly and Company $23,228.00 02/22/2022 Covered Recipient Physician ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3372689 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 917809017
Principal investigator 1 Eli Lilly and Company $4,211.00 02/03/2022 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3372689 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 917828813
Principal investigator 1 Eli Lilly and Company $13,198.00 01/11/2022 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 917826751
Recipient Eli Lilly and Company $51,903.00 01/07/2022 Covered Recipient Physician A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 917809013